Skip Navigation LinksHome > February 20, 2004 - Volume 18 - Issue 3 > HIV-2 protease sequences of subtypes A and B harbor multiple...
AIDS:
Clinical Science

HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1

Pieniazek, Danuta; Rayfield, Marka; Hu, Dale Jb; Nkengasong, John Nb,c; Soriano, Vincentd; Heneine, Walid; Zeh, Clement; Agwale, Simon Me; Wambebe, Charlesf; Odama, Lilianae; Wiktor, Stefan Zg

Free Access
Article Outline
Collapse Box

Author Information

From the HIV and Retrovirology Branch and the aOffice of the Director, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Atlanta, Georgia, and the bDivision of HIV/AIDS Prevention and cProjet RETRO-CI, Ivory Coast, the dInstituto de Salud Carlos III, Madrid, Spain, the eNational Institute of Pharmaceutical Research and Development and the fFederal Ministry of Health, Abuja, Nigeria, and the gGlobal AIDS Program, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Correspondence to D. Pieniazek, 1600 Clifton Road, Mail Stop G19, Atlanta, GA 30333, USA.

Received: 8 May 2003; revised: 31 July 2003; accepted: 19 August 2003.

Collapse Box

Abstract

Background: HIV-1 protease inhibitors (PI) have been used for treating HIV-2-infected persons but little is known about amino acid mutations associated with PI resistance in HIV-2 and whether they are similar to those seen in HIV-1.

Objective: To determine the frequency of HIV-1 PI resistance-associated mutations in PI-naive HIV-2-infected individuals.

Design: Using PCR, protease genes were amplified from 76 individuals, directly sequenced, phylogenetically subtyped, and translated into amino acids to analyze PI-associated major and minor mutations.

Results: Of the 76 HIV-2 sequences, 68% belonged to subtype A and 32% to subtype B. All sequences contained at least four codon changes giving substitutions at 10, 30, 32, 36, 46, 47, 71 or 77. The frequency of these mutations was similar in subtype A and B viruses. Two major resistance-conferring mutations, 30N and 46I, were identified in one (1%) and 68 (89%) specimens, respectively. Minor mutations 10V/I, 32I, 36I, 47V, and 71V were predominant (89%–100%), followed by the rare mutation 77I (1%). Of the 76 strains, 89% harbored multiple PI resistance-associated substitutions comprising both the major 46I and minor mutations: 10V/I, 32I, 36I, 46I, 47V, 71V (76%); 10V, 32I, 36I, 46I, 47V (9%); and 10V, 32I, 36I, 46I, 47V 71V, 77I (1.3%), 10V, 32I, 46I, 47V, 71V (1.3%), and 10V, 30N, 32I, 36I, 46I, 47V, 71V (1.3%). The remaining 11% of the sequences had patterns with only minor mutations: 10V, 32I, 36I, 47V, 71V (9%) and 10V, 32I, 36I, 47V (1.3%).

Conclusions: The high frequency of multiple PI-associated substitutions represent natural polymorphisms occurring in HIV-2 strains of subtypes A and B. Phenotypic and clinical studies are needed to determine the relevance of these substitutions.

Back to Top | Article Outline

Introduction

HIV-2, the second causative agent of AIDS, has been classified into seven phylogenetic subtypes [1–3] identified mainly in West Africa [4]. Subtype A is prevalent in the majority of countries [4], whereas a predominance of subtype B was suggested in Ivory Coast [5]. For the remaining subtypes, C–G, only single viral strains have been reported. The spread of HIV-2 to Europe, Asia, and the Americas occurs slowly but continually. Population migration, international travel, historical socio-economic connections between European countries and former colonies, and expatriates returning to countries after living and working in HIV-2-endemic regions are considered responsible for spreading HIV-2 worldwide [4,6–8]. The majority of HIV-2 infections in Europe and North America have been identified among African immigrants or nationals having sex with people who have lived in West Africa [4,9–14]. A noteworthy exception is Portugal, where more than 60% of new HIV-2 infections were not linked directly to African contacts [9], indicating that HIV-2 is spreading among the indigenous population [15]. Since Portugal has a high number of HIV-2 infections, up to 4.5% of this country's AIDS cases, Portugal might serve as a source for this infection in Europe [9,16]. Likewise, the spread of HIV-2 in India is steadily increasing, especially among injecting drug users [17]. The simultaneous presence of HIV-1 and HIV-2 in certain regions leads to mixed HIV-1/HIV-2 infections [18–20].

The clinical management of HIV-1 infections has improved significantly with combinations of antiretroviral (ARV) drugs, including protease inhibitors (PI) [21]. In contrast, there is no proven ARV drug therapy for HIV-2. HIV-2 isolates are resistant to at least some non-nucleoside reverse transcriptase inhibitors [22]. Recently, HIV-1 PI have been used to treat HIV-2-infected persons [23–25] based on the assumption that these drugs are equally active on HIV-2 protease (PR). However, little is know about mutations associated with PI resistance in HIV-2 and whether they are similar to those seen in HIV-1. In this report, we present the first large-scale description and genetic characterization of HIV-2 PR sequences of two major subtypes, A and B, isolated from ARV-naive individuals as a baseline for comparison when following HIV-2-infected persons after drug treatments.

Back to Top | Article Outline

Materials and methods

Specimens

From 1986 to1999, peripheral blood mononuclear cells (PBMC) were collected from 76 HIV-2-infected drug-naive individuals living in Africa (n = 65; Ivory Coast, 50; Nigeria, 13; Guinea Bissau, two), Asia (Lebanon, one), Europe (Portugal, seven), and the Americas (Brazil, two; USA, one). All specimens were a part of HIV-2 genetic variant studies approved by the Institutional Review Board [5,7,26]. Seventy-four percent of the specimens harbored only HIV-2, and 26% were from HIV-1/HIV-2 dual infections.

Back to Top | Article Outline
Amplification, sequencing, and phylogenetic analysis

HIV-2 DNA was extracted and used for nested PCR amplification of PR with outside DP20-forward and DP21-reverse and nested DP26a-forward and DP27-reverse primers [5]. To minimize false-positive PCR results, disposable laboratory gowns and gloves were used, pre- and post-PCR materials were processed in separate rooms, and UV irradiation was used to treat PCR chemicals and tubes. Negative controls consisting of uninfected viral DNA and water were used in each batch of PCR. When investigated samples were closely related (< 3%), they were reevaluated using additional vials of patient PBMC. PCR products were directly sequenced using DP26a-forward and DP27-reverse-nested PCR primers and resolved on an automated DNA sequencer ABI model 377 (Applied Biosystems, Foster City, California, USA). The PR sequences were aligned by the CLUSTALW multiple sequence alignment program and used for phylogenetic analysis [27]. HIV-1MN (M17449) was used as outgroup. GenBank accession numbers of sequences presented in this study are: L08459, L08461, L08462, L08465, L08466, AF026 912; AF073844-73874; AY102844-2856; AY343991-344017.

Back to Top | Article Outline
Amino acid analysis

The aligned DNA sequences were translated to amino acids using the Genetic Data Environment package [28]. The first and the last seven amino acids of PR genes are parts of the 5′ and 3′ sequence primers, respectively, and were excluded from analysis. Conservative and non-conservative substitutions were estimated using the Meyers and Miller model [29], which identified the nine amino acid groups: A, S, T, C; D, E; N, Q; R, K; I, L, M, V; F, Y, W; G; P; and H. Information on major and minor mutations associated with HIV-1 PI resistance was obtained from the latest literature [30].

Back to Top | Article Outline

Results

Phylogenetic analysis of PR genes indicated that 52 (68%) of the 76 sequences were of subtype A viruses and 24 (32%) were of subtype B (Fig. 1). Of subtype A, 56% (29/52) were from Ivory Coast, 21% (11/52) were from Nigeria, 4% (2/52) were from each of Guinea Bissau and Brazil, 13% (7/52) were from Portugal, and 2% (1/52) were from the USA. Of subtype B, 88% (21/24) were from Ivory Coast, 8% (2/24) were from Nigeria, and 4% (1/24) were from Lebanon.

Fig. 1
Fig. 1
Image Tools

Genetic distance analysis revealed that some PR sequences of subtype A were closely related. Two specimens IC310059 and IC310060 collected in 1988 from patients living in Ivory Coast showed similarity of 99.7% [5] and were closely (98%) related to specimen US-NJ (HIV-1888) collected in 1989 in New Jersey from an African immigrant. Information on relationships between patients harboring these strains and their sexual partners was not available. Similarly, 11 strains collected in 1998 from unrelated individuals living in 10 Nigerian states show close relationships (range, 97.2%–99.6%). These findings are unlikely to be result of contamination in the laboratory because similar data were obtained when independent PCR amplifications were done on different days using the original and the second vial of patient PBMC. Also, contamination during blood collection was rather unlikely because a disposable Vacutainer system was used to obtain each blood sample. Interestingly, PR gene sequences IC310059 and IC310060 revealed 100% relationships with ROD strain found in Senegal in 1985 whereas our Nigerian sequences formed a strong (98%) monophyletic cluster with the reference sequence of NIHZ strain (data not shown) identified in 1986 in Guinea Bissau. These results indicated that the observed close relationships between our PR sequences and the reference sequences, which were retrieved from GenBank and used as references of subtype A in phylogenetic analysis, may reflect a common origin. As changes in the conserved PR gene are very small over time (< 1% over 4 years in HIV-1; unpublished data), this viral region may be useful to study the origin, evolution, and dissemination of HIV subtype worldwide as we previously suggested [5].

To compare amino acid genetic diversity between HIV-2 strains, we aligned HIV-2 PR sequences of subtypes A and B with subtype A reference HIV-2ROD (Fig. 2). This analysis showed minimal amino acid variation within domains of PR that are functionally important in HIV-1, such as the enzyme active region (residues 21–33), the top of the flap (residues 47–56), and the second loop of the β sheet (residues 78–88) [31]. In contrast, there was a broad diversity in other areas of the PR enzyme. Overall, 54% (54/99) of amino acid codons had at least one change in this HIV-2 sampling. A higher variation (43%) was observed for subtype A than subtype B (32%) strains, but this difference was not significant (P = 0.42). Also, PR subtype A differed from subtype B at five amino acid positions (12, 43, 67, 91, and 92) that most likely reflect HIV-2 PR subtype signature patterns similarly to patterns of HIV-1 PR subtype B and non-B viruses [32].

Fig. 2
Fig. 2
Image Tools

To evaluate differences between PR of HIV-2 and HIV-1, our HIV-2 and HIV-1 [33] consensus amino acid sequences were aligned (Fig. 3). This analysis showed dissimilarities at 46 positions, counting 35 conservative and 65 non-conservative substitutions. Of these 46 changes, 36 (78%) occurred in HIV-2 at positions covering the variable domains of HIV-1 PR. The remaining 10 (22%) changes were located at positions that overlap the functionally important HIV-1 PR regions: codons 22, 31-33 at the active domain; codons 47, 55, and 56 at the top of the flap; and codons 79, 82, and 85 at the second loop of the β sheet. Overall, this analysis revealed > 45% differences at the protein level between HIV-2 and HIV-1, data similar to results in other reports [25].

Fig. 3
Fig. 3
Image Tools

We examined HIV-2 sequences for the presence of major (D30N, M46I, G48V, I50V, V82A/F/S/T/V, I84V, and L90M) and minor (L10I/V/F/R, K20R/M, L24I, V32I, L33F, M36I, M46L, I47V, I54V, L63P, A71V/T, G73S, V77I, and N88D/S) substitutions, which are associated with PI resistance in HIV-1 subtype B to saquinavir, ritonavir, indinavir, nelfinavir, and amprenavir [30]. This analysis revealed such substitutions at eight positions of HIV-2, 10←V/I, 30←N, 32←I, 36←I, 46←I, 47←V, 71←V, and 77←I (Fig. 2). Two major substitutions, 30N and 46I, were identified in this sampling but their frequency differed. While 30N was present in only one strain (1.3%, 1/76) of HIV-2 subtype B, substitution 46I was in the majority (89%, 68/76) of strains, including 83% (43/52) of subtype A and 100% of subtype B (Fig. 4).

Fig. 4
Fig. 4
Image Tools

The frequency of minor mutations at codons 10, 32, 36, 47, and 71 was 100% for substitutions 10V/I, 32I, and 47V; 99% (75/76) for 36I; and 89% (68/76) for 71V (Fig. 4). In contrast, 77I substitution was in only one HIV-2 of subtype A from Ivory Coast. Moreover, at least 96% of HIV-2 strains harbored substitutions not seen in HIV-1 at PI-conferring resistance codons such as 20←V, 33←V, 63←E, 73←A, V77←T, and 82←I (Fig. 2). Overall, this analysis indicated that 12 of the 20 codons associated with PI resistance in HIV-1 were occupied in HIV-2 by PI major and minor mutations as well as substitutions not observed in HIV-1.

The majority of HIV-2 strains (89%, 68/76) harbored five multiple PI resistance-associated mutation patterns comprising both the major 46I and different minor mutations. The most prevalent pattern was 10V/I, 32I, 36I, 46I, 47V, 71V (76%, 58/76), followed by 10V, 32I, 36I, 46I, 47V (9%, 7/76) and by 10V, 32I, 36I, 46I, 47V, 71V, 77I; 10V, 32I, 46I, 47V, 71V; and 10V, 30N, 32I, 36I, 46I, 47V, 71V (1.3%, 1/76, for each). The remaining 11% (8/76) strains had patterns comprising minor mutations only: 10V, 32I, 36I, 47V, 71V (9%, 7/76) and 10V, 32I, 36I, 47V (1.3%). Taken together, this analysis documented that all 76 HIV-2 strains carried numerous mutations associated with PI resistance in HIV-1 that range from four to eight substitutions per strain and that 46I substitutions, a major resistance mutation in HIV-1, was present in 89% of HIV-2 sequences.

As our data showed that HIV-2 PR sequences harbored different PI-multiple mutational patterns, we further analyzed their distributions according to country of specimen collection. We found that HIV-2 strains from different geographic regions harbored similar multiple-mutation patterns that are associated with resistance to PI in HIV-1. For example, the most common pattern comprising major (46I) and five minor mutations (10V/I, 32I, 36I, 47V, and 71V) was found in 38 of 50 HIV-2 from Ivory Coast, in all 13 Nigerian specimens, in one of the two samples from Guinea Bissau, and in six of 11 samples collected outside Africa including one strain from the USA, one of two strains from Brazil, and four of seven strains from Portugal. Likewise, less frequent patterns with or without 46I major mutation were in HIV-2 from Ivory Coast, Guinea Bissau, Lebanon, Portugal, and Brazil.

Back to Top | Article Outline

Discussion

This study provides the most comprehensive data to date on genetic diversity of HIV-2 PR genes among HIV-2-infected individuals in Ivory Coast, Nigeria, Guinea Bissau, Lebanon, Portugal, Brazil, and the USA. Our data revealed a similar range of amino acid variation within PR genes for both HIV-2 subtype A and B regardless of geographic region and confirmed differences in more than 45% of amino acid codons when compared with HIV-1 PR. We also showed that amino acid changes in HIV-2 were located at positions that overlap the functionally important domains in HIV-1 PR; such substitutions may be critical when designing PI for HIV-1 subtype B. It seems that previously reported differences between HIV-1 and HIV-2 PR enzymes with respect to substrate specificity and affinity to pseudopeptidil inhibitors [34] could be due to dissimilarities at the protein level as presented here. Furthermore, 89% of all HIV-2 strains harbored both the major and at least four minor mutations associated with PI resistance in HIV-1, while the remaining 11% had multiple minor mutations only. The high frequency of PI-associated substitutions indicates natural polymorphisms occurring in PI-naive individuals infected with HIV-2 subtypes A and B.

Comparative analysis of amino acids at 20 codons, which are linked to PI resistance in HIV-1, with those positions in HIV-2 PR sequences, provided several observations. First, the major PI resistance substitution 46I, which is associated with indinavir resistance in HIV-1, was identified in 89% of the HIV-2 sequences, whereas is rarely (< 1%) observed in global drug-naive collections of HIV-1 ([32,33]; http://hivdb.stanford.edu). Second, PI minor substitutions 10V or 10I, 32I, 47V, and 71V, which contribute to indinavir, ritonavir, saquinavir, nelfinavir or amprenavir resistance, were present either in all or in the majority (> 85%) of HIV-2 sequences, whereas these mutations are infrequent in HIV-1. Only the frequency of substitution 36I, which is associated with ritonavir and nelfinavir resistance, was similar in HIV-2 (99%) and HIV-1 non-B (83%) strains. Third, all HIV-2 PR sequences carried multiple PI resistance-associated mutations, of which 89% of strains had also the major 46I substitution that predominantly occurred in combination with five minor mutations (10V/I, 32I, 36I, 47V, 71V). In contrast, the majority (85%) of HIV-1 strains harbored only a single minor substitution (e.g., 36I, 63P or 77I) followed by about 25% dual or triple mutations (e.g., 63P, 77I or 36I, 63P or 10V/I, 36I, 63P) [33]. Recently published data indicate that as few as four PI mutations can be associated with a high-level resistance for HIV-1 [35].

Genetic characterization of viral PR sequences pointed out the distinctions in amino acid compositions between HIV-1 and HIV-2 and raises the question of whether PI, which were developed for treatment of HIV-1 subtype B infections through the specific inhibition of PR activity of these viruses [36], would also be effective in the treatment of HIV-2-infected individuals. A recent in vitro phenotypic study ([37]; http://www.mediscover.net) showed that PI indinavir, ritonavir, and saquinavir inhibited equally HIV-2 subtype A (ROD) and subtype B (ECHO) reference strains and HIV-1 wild-type, although both HIV-2 strains harbor the major 46I mutation and four minor substitutions (10V, 32I, 36I, 71V) conferring HIV-1 resistance [30]. Thus, these results suggest that there are other compensatory mutations in HIV-2 ROD and ECHO that make the PR enzyme susceptible to PI despite the presence of HIV-1 PI mutations. In contrast, susceptibility to nelfinavir was reduced by 3.0-fold and susceptibility to amprenavir was reduced by 4.3 and 9.0-fold for ROD and ECHO strains, respectively. These reductions were not caused as in HIV-1 by the major mutations 30N, 90M, 50V or 84V, which are absent in both HIV-2 strains. It is not clear, however, if multiple minor mutations (10V, 32V, 36I, 46I, 71V) in these HIV-2 strains caused resistance to nelfinavir and amprenavir. Therefore, these data indicate that substitutions associated with resistance to PI in HIV-2 might differ from those in HIV-1.

The data on antiretroviral treatment of HIV-2 infections in humans are very limited and often difficult to interpret, mainly because of variations in protocols used in clinical approaches, differences in timing of therapy initiation (patients with different stages of disease ranging from asymptomatic to AIDS), and limitations in diagnostic and clinical markers monitoring the response to drug therapies [23–25]. Also, interpretation of clinical results might be obscured by treatment of patients infected with both HIV-1 and HIV-2 strains, whose numbers have increased in West Africa and India [38,39]. For example, some patients failed to respond to ARV therapies, demonstrated by no decrease in viral loads during highly active ARV treatment including the PI nelfinavir [40] or by development of resistance to the reverse transcriptase inhibitor lamuvidine and the PI saquinavir [23]. In contrast, other studies have shown a fall in viral load and an increase in CD4 cell counts after regimens with nelfinavir [23] and indinavir [24,40]. Long-term evaluation of the impact of HIV-1 PI on progression of disease in HIV-2-infected patients needs to be conducted in closely monitored clinical trials.

Data on genotypic characterization of PI resistance mutations in HIV-2 PR sequences isolated from PI-treated patients are also limited. Analyses of four patients treated for at least 6 months with ARV showed that three individuals treated with ritonavir or indinavir had the same substitutions at 20 codons within PR sequences as in reference drug-naive subtype A ROD, NIHZ, and ISY strains [25]. In the remaining one patient treated with indinavir, nelfinavir, and saquinavir different substitutions were at positions 54 (M) and 82 (F) of PR, but it is unclear whether such changes occurred during treatment or if they were originally present in the HIV-2 strain of this patient. As it is uncertain if amino acid mutations associated with PI resistance in HIV-2 are similar to those seen in HIV-1, evaluation of genetic diversity of PR sequences from drug-treated HIV-2-infected patients should include all amino acid positions and not only those at 20 codons. The HIV-2 database for drug-naive subtype A and subtype B PR sequences reported here may be useful in pre-selection of HIV-2 PI resistance mutations in PI-treated patients.

In summary, our data provide new information on HIV-2 genetic variation associated with PI resistance in HIV-1. The identification of multiple PI-associated substitutions in all HIV-2 subtype A and subtype B strains documents differences between HIV-2 and HIV-1 PR genes. These data may have important implications for the choice of ARV therapy. Our HIV-2 PR sequence database from drug-naive persons may be useful in phenotypic and clinical studies for determining pathways for the development of PI resistance during PI treatment.

Back to Top | Article Outline

Acknowledgment

The authors gratefully acknowledge K. Distel for excellent editorial assistance.

Back to Top | Article Outline

References

1. Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994, 68:7433–7447.

2. Chen Z, Luckay A, Sodora DL, Telfer P, Reed P, Gettie A, et al. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol 1997, 71:3953–3960.

3. Yamaguchi J, Devare SG, Brennan CA. Identification of a new HIV-2 subtype based on phylogenetic analysis of full-length genomic sequence. AIDS Res Hum Retroviruses 2000, 16: 925–930.

4. Kanki PJ, Peeters M, Gueye-Ndiaye A. Virology of HIV-1 and HIV-2: implications for Africa. AIDS 1997, 11:S33–S42.

5. Pieniazek D, Ellenberger D, Janini LM, Ramos AC, Nkengasong J, Sassan-Morokro M, et al. Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 1999, 15:603–608.

6. Guman M, al Karmi T, Lukic ML, Behbehani K. Detection of HIV-2 infection in the Gulf region. AIDS Res Hum Retroviruses 1990, 6:1469–1470.

7. Pieniazek D, Baggs J, Hu DJ, Matar GM, Abdelnoor AM, Mokhbat JE, et al. Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon. Emerg Infect Dis 1998, 4:649–656.

8. Kim SS, Kim EY, Park KY, Suh SD, Park HK, Shin YO, et al. Introduction of human immunodeficiency virus 2 infection into South Korea. Acta Virol 2000, 44:15–22.

9. Soriano V, Gomes P, Heneine W, Holguin A, Doruana M, Antunes R, et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000, 61:111–116.

10. van der Ende ME, Schutten M, Ly TD, Gruters RA, Osterhaus AD. HIV-2 infection in 12 European residents: virus characteristics and disease progression. AIDS 1996, 10:1649–1655.

11. Machuca A, Soriano V, Gutirrez M, Holguin A, Aguilera A, Caballero E, et al. Human immunodeficiency virus type 2 infection in Spain. The HIV-2 Spanish Study Group. Intervirology 1999, 42:37–42.

12. Damond F, Apetrei C, Robertson DL, Souquiere S, Lepretre A, Matheron S, et al. Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france. Virology 2001, 280:19–30.

13. Bruckova M, Kopecka D, Syrucek L, Vojtechovsky K, Petkov V. HIV-2 infection in Czechoslovakia. Acta Virol 1989, 33:191.

14. O'Brien TR, Polon C, Schable CA, VanDevanter N, Rayfield MA, Wallace D, et al. HIV-2 infection in an American. Aids 1991, 5:85–88.

15. Quinn TC. Population migration and the spread of types 1 and 2 human immunodeficiency viruses. Proc Natl Acad Sci USA 1994, 91:2407–2414.

16. Smallman-Raynor M, Cliff A. The spread of human immunodeficiency virus type 2 into Europe: a geographical analysis. Int J Epidemiol 1991, 20:480–489.

17. Singh NB, Panda S, Naik TN, Agarwal A, Singh HL, Singh YI, et al. HIV-2 strikes injecting drug users (IDUs) in India. J Infect 1995, 31:49–50.

18. George JR, Ou CY, Parekh B, Brattegaard K, Brown V, Boateng E, et al. Prevalence of HIV-1 and HIV-2 mixed infections in Cote d'Ivoire. Lancet 1992, 340:337–339.

19. Sarr AD, Sankale JL, Gueye-Ndiaye A, Essex M, Mboup S, Kanki PJ. Genetic analysis of HIV type 2 in monotypic and dual HIV infections. AIDS Res Hum Retroviruses 2000, 16:295–298.

20. Grez M, Dietrich U, Balfe P, von Briesen H, Maniar JK, Mahambre G, et al. Genetic analysis of human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. J Virol 1994, 68:2161–2168.

21. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860.

22. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994, 243:369–387.

23. Smith NA, Shaw T, Berry N, Vella C, Okorafor L, Taylor D, et al. Antiretroviral therapy for HIV-2 infected patients. J Infect 2001, 42:126–133.

24. Clark NM, Dieng Sarr A, Sankale JL, Kanki PJ, Kazanjian P, Winfield R, et al. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy. AIDS 1998, 12:2506–2507.

25. Rodes B, Holguin A, Soriano V, Dourana M, Mansinho K, Antunes F, et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000, 38: 1370–1374.

26. Pieniazek D, Peralta JM, Ferreira JA, Krebs JW, Owen SM, Sion FS, et al. Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction. AIDS 1991, 5:1293–1299.

27. Felsenstein J. PHYLIP-Phylogeny interference package (vesion 3.2). Cladistics 1989, 5:164–166.

28. Smith SW, Overbeek R, Woese CR, Gilbert W, Gillevet PM. The genetic data environment an expandable GUI for multiple sequence analysis. Comput Appl Biosci 1994, 10:671–675.

29. Myers EW, Miller W. Optimal alignments in linear space. Comput Appl Biosci 1988, 4:11–17.

30. D'Aquila RT, Shapiro JM, Brun-Vezinet F, Cloted B, Conway B, Demeter ML, et al. Drug resistance mutations in HIV-1. Topics HIV Med 2002, 10:11–15.

31. Fontenot G, Johnston K, Cohen JC, Gallaher WR, Robinson J, Luftig RB. PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains. Virology 1992, 190:1–10.

32. Fonjungo PN, Mpoudi EN, Torimiro JN, Alemnji GA, Eno LT, Lyonga EJ, et al. Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features. J Clin Microbiol 2002, 40:837–845.

33. Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000, 14:1489–1495.

34. Tomasselli AG, Hui JO, Sawyer TK, Staples D J, Bannow C, Reardon IM, et al. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem 1990, 265:14675–14683.

35. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross- resistance and reduced replication capacity. AIDS 2002, 16: 1009–1017.

36. Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 1993, 62:543–585.

37. Witvrouw M, Pannecouque C, De Clercq E, Switzer WM, Folks TM, Heneine W. Susceptibility of HIV-2 to approved and experimental antiretroviral drugs: implications for treatment. Antiretroviral Ther 2002, 7:S118.

38. De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, Maran M, et al. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 1993, 270:2083–2086.

39. Kamat HA, Banker DD, Koppikar GV. Increasing prevalence of HIV-2 and dual HIV-1-2 infections among patients attending various outdoor patient departments in Mumbai (Bombay). Ind J Public Health 1999, 43:85–86.

40. Adje-Toure CA, Cheingsong R, Garcia-Lerma G, Eholie S, Borget M-Y, Bouchez J-M, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Ivory Coast. AIDS 2003, 17:S49–S54.

Cited By:

This article has been cited 28 time(s).

AIDS Research and Human Retroviruses
Natural polymorphisms of HIV type 2 pol sequences from drug-naive individuals
Parreira, R; Monteiro, F; Padua, E; Piedade, J; Venenno, T; Paixao, MT; Esteves, A
AIDS Research and Human Retroviruses, 22(): 1178-1182.

Journal of Infectious Diseases
HIV-1 genetic diversity surveillance in the United States
Bennett, D
Journal of Infectious Diseases, 192(1): 4-9.

Brazilian Journal of Infectious Diseases
A review of the epidemiology, prevention and treatment of human immunodeficiency virus infection in Nigeria
Entonu, PE; Agwale, SM
Brazilian Journal of Infectious Diseases, 11(6): 579-590.

Bmc Infectious Diseases
Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database
Ruelle, J; Roman, F; Vandenbroucke, AT; Lambert, C; Fransen, K; Echahidi, F; Pierard, D; Verhofstede, C; Van Laethem, K; Delforge, ML; Vaira, D; Schmit, JC; Goubau, P
Bmc Infectious Diseases, 8(): -.
ARTN 21
CrossRef
AIDS Research and Human Retroviruses
Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients
Xu, L; Anderson, J; Ferns, B; Cook, P; Wildfire, A; Workman, J; Graham, S; Smit, E
AIDS Research and Human Retroviruses, 24(7): 1003-1007.
10.1089/aid.2007.0303
CrossRef
Current Hiv Research
HIV genetic diversity: Biological and public health consequences
Butler, IF; Pandrea, I; Marx, PA; Apetrei, C
Current Hiv Research, 5(1): 23-45.

Antimicrobial Agents and Chemotherapy
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors
Desbois, D; Roquebert, B; Peytavin, G; Damond, F; Collin, G; Bernard, A; Campa, P; Matheron, S; Chene, G; Brun-Vezinet, F; Descamps, D
Antimicrobial Agents and Chemotherapy, 52(4): 1545-1548.
10.1128/AAC.01284-07
CrossRef
Antimicrobial Agents and Chemotherapy
Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2
Ntemgwa, ML; Toni, TD; Brenner, BG; Camacho, RJ; Wainberg, MA
Antimicrobial Agents and Chemotherapy, 53(9): 3611-3619.
10.1128/AAC.00154-09
CrossRef
Protein Science
Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease
Louis, JM; Ishima, R; Aniana, A; Sayer, JM
Protein Science, 18(): 2442-2453.
10.1002/pro.261
CrossRef
Antimicrobial Agents and Chemotherapy
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir
Masse, S; Lu, XZ; Dekhtyar, T; Lu, LJ; Koev, G; Gao, F; Mo, HM; Kempf, D; Bernstein, B; Hanna, GJ; Molla, A
Antimicrobial Agents and Chemotherapy, 51(9): 3075-3080.
10.1128/AAC.00146-07
CrossRef
Chemical Biology & Drug Design
Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use
Brower, ET; Bacha, UM; Kawasaki, Y; Freire, E
Chemical Biology & Drug Design, 71(4): 298-305.
10.1111/j.1747.0285.2008.00647.x
CrossRef
AIDS Patient Care and Stds
Screening and management of HIV-2-infected individuals in Northern Italy
Costarelli, S; Torti, C; Rodella, A; Baldanti, F; Paolucci, S; Lapadula, G; Manca, N; Quiros-Roldan, E; Izzo, I; Carosi, G
AIDS Patient Care and Stds, 22(6): 489-494.
10.1089/apc.2007.0149
CrossRef
M S-Medecine Sciences
Genetic diversity and phylogeographic distribution of SIV: how to understand the origin of HIV
Peeters, M; Chaix, ML; Delaporte, E
M S-Medecine Sciences, 24(): 621-628.

Clinical Infectious Diseases
Emergence of Multiclass Drug-Resistance in HIV-2 in Antiretroviral-Treated Individuals in Senegal: Implications for HIV-2 Treatment in Resouce-Limited West Africa
Gottlieb, GS; Badiane, NMD; Hawes, SE; Fortes, L; Toure, M; Ndour, CT; Starling, AK; Traore, F; Sall, F; Wong, KG; Cherne, SL; Anderson, DJ; Dye, SA; Smith, RA; Mullins, JI; Kiviat, NB; Sow, PS
Clinical Infectious Diseases, 48(4): 476-483.
10.1086/596504
CrossRef
Journal of Clinical Microbiology
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors
Damond, F; Brun-Vezinet, F; Matheron, S; Peytavin, G; Campa, P; Pueyo, S; Mammano, F; Lastere, S; Farfara, I; Simon, F; Chene, G; Descamps, D
Journal of Clinical Microbiology, 43(1): 484-487.
10.1128/JCM.43.1.484-487.2005
CrossRef
Hiv Medicine
Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV
Hawkins, D; Blott, M; Clayden, P; de Ruiter, A; Foster, G; Gilling-Smith, C; Gosrani, B; Lyall, H; Mercey, D; Newell, ML; O'Shea, S; Smith, R; Sunderland, J; Wood, C; Taylor, G
Hiv Medicine, 6(): 107-148.

Journal of Antimicrobial Chemotherapy
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy
Rodes, B; Sheldon, J; Toro, C; Jimenez, V; Alvarez, MA; Soriano, V
Journal of Antimicrobial Chemotherapy, 57(4): 709-713.
10.1093/jac/dkl034
CrossRef
Retrovirology
HIV-2 Protease resistance defined in yeast cells
Ben M'Barek, N; Audoly, G; Raoult, D; Gluschankof, P
Retrovirology, 3(): -.
ARTN 58
CrossRef
Clinical Infectious Diseases
Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2
Rodes, B; Toro, C; Jimenez, V; Soriano, V
Clinical Infectious Diseases, 41(2): E19-E21.

AIDS Research and Human Retroviruses
Genetic Polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso
Ruelle, J; Sanou, M; Liu, HF; Vandenbroucke, AT; Duquenne, A; Goubau, P
AIDS Research and Human Retroviruses, 23(8): 955-964.
10.1089/aid.2007.0034
CrossRef
Trends in Pharmacological Sciences
HIV-1 protease inhibitors: effects on HIV-2 replication and resistance
Menendez-Arlas, L; Tozser, J
Trends in Pharmacological Sciences, 29(1): 42-49.
10.1016/j.tips.2007.10.013
CrossRef
Journal of Molecular Biology
Structural Evidence for Effectiveness of Darunavir and Two Related Antiviral Inhibitors against HIV-2 Protease
Kovalevsky, AY; Louis, JM; Aniana, A; Ghosh, AK; Weber, IT
Journal of Molecular Biology, 384(1): 178-192.
10.1016/j.jmb.2008.09.031
CrossRef
AIDS Research and Human Retroviruses
HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal
Gottlieb, GS; Hawes, SE; Wong, KG; Raugi, DN; Agne, HD; Critchlow, CW; Kiviat, NB; Sow, PS
AIDS Research and Human Retroviruses, 24(6): 857-864.
10.1089/aid.2008.0015
CrossRef
Antimicrobial Agents and Chemotherapy
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors
Ntemgwa, M; Brenner, BG; Oliveira, M; Moisi, D; Wainberg, MA
Antimicrobial Agents and Chemotherapy, 51(2): 604-610.
10.1128/AAC.00870-06
CrossRef
Antimicrobial Agents and Chemotherapy
Complex Patterns of Protease Inhibitor Resistance among Antiretroviral Treatment-Experienced HIV-2 Patients from Senegal: Implications for Second-Line Therapy
Raugi, DN; Smith, RA; Ba, S; Toure, M; Traore, F; Sall, F; Pan, C; Blankenship, L; Montano, A; Olson, J; Badiane, NMD; Mullins, JI; Kiviat, NB; Hawes, SE; Sow, PS; Gottlieb, GS
Antimicrobial Agents and Chemotherapy, 57(6): 2751-2760.
10.1128/AAC.00405-13
CrossRef
AIDS
CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort
the ANRS CO5 HIV2 Cohort Study Group, ; Matheron, S; Damond, F; Benard, A; Taieb, A; Campa, P; Peytavin, G; Pueyo, S; Brun-Vezinet, F; Chene, G
AIDS, 20(3): 459-462.
10.1097/01.aids.0000199829.57112.2f
PDF (174) | CrossRef
AIDS
A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa
Gottlieb, GS; Eholié, S; Nkengasong, JN; Jallow, S; Rowland-Jones, S; Whittle, HC; Sow, PS
AIDS, 22(16): 2069-2072.
10.1097/QAD.0b013e32830edd44
PDF (84) | CrossRef
AIDS
High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART
Rodés, B; Toro, C; Sheldon, JA; Jiménez, V; Mansinho, K; Soriano, V
AIDS, 20(1): 127-129.

PDF (1410)
Back to Top | Article Outline
Keywords:

HIV-2; subtypes; protease; inhibitors; resistance amino-acid mutations

© 2004 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.